|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
Recent | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositionsBelow are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 02/27/2014 > 203 patent applications in 109 patent subcategories.
20140056807 - Large oncosomes in human tumors and in circulation in patients with cancer: The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes in a subject in need thereof.... Agent: Cedars-sinai Medical Center
20140056806 - Self-assembling biomimetic hydrogels having bioadhesive properties: The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of... Agent: Rowan University
20140056808 - Neoantibodies for diagnosing tissue injury: A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.... Agent: Novelmed Therapeutics, Inc.
20140056809 - Treatment and diagnosis of macrophage mediated disease: where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for... Agent: Purdue Research Foundation
20140056810 - Conjugates and their uses in molecular imaging: The present invention relates to bifunctional compounds, the bifunctional compounds for use in molecular imaging and therapy, methods of molecular imaging using the bifunctional compounds and kits including the bifunctional compounds for use molecular imaging. The bifunctional compounds have a tripodal hydroxypyridinone chelating portion and may be conjugated to a... Agent: King's College London
20140056812 - Imaging beta cell mass: The present disclosure provides compositions and methods based on peptide-detectable agent conjugates that are useful for imaging beta cell mass.... Agent: The General Hospital Corporation
20140056811 - New cell-penetrating peptides and uses thereof: The present invention is related to peptides, which are suitable for use as cell-penetrating peptides (CPPs), variants thereof and/or complexes, fusion molecules and/or conjugates comprising same, use thereof for manufacture of compositions for diagnosing, treating and/or preventing of medical conditions.... Agent: Compugen Ltd.
20140056813 - Nanoparticles delivery systems, preparation and uses thereof: The present application relates to thermosensitive liposomes encapsulating nanoparticles which can be used in the health sector, in particular in human health. The invention also relates to pharmaceutical and diagnostic compositions comprising thermosensitive liposomes as defined previously, as well as to their uses.... Agent: Nanobiotix
20140056814 - Method of constructing animal having cancer cells transplanted thereinto: A cell culture support is first prepared that is coated on a surface with a polymer the hydration force of which changes in a temperature range of 0-80° C.; cancer cells are then cultivated on the support in a temperature region where the polymer has weak hydration force; thereafter, the... Agent:
20140056815 - Methods to regulate polarization and enhance function of cells: Minimally invasive delivery with intercellular and/or intracellular localization of nano- and micro-particle solar cells within and among excitable biological cells to controllably regulate membrane polarization and enhance function of such cells. The cells include retinal and other excitable cells.... Agent:
20140056819 - Nanoparticulate compositions for diagnostic imaging: wherein R1 and R2 are independently at each occurrence a C1-C3 alkyl group; R3 is independently at each occurrence a hydrogen or a C1-C3 alkyl group; R4 is a C1-C5 aliphatic radical, a C7-C12 aromatic radical, or a C5-C10 cycloaliphatic group; n is 0, 1, 2 or 3; q is... Agent: General Electric Company
20140056820 - Transport agents for crossing the blood-brain and into brain cancer cells and methods of use thereof: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic... Agent: The Board Of Trustees Of The University Of Illinois
20140056822 - Dna dendrimers as thermal ablation devices: DNA dendrimers for targeted delivery of radiation absorbing nanoparticles and thermal ablation of cells and tissues are provided. Also provided are methods of making and methods of using the DNA dendrimers.... Agent: Genisphere, LLC
20140056816 - Implants and biodegradable fiducial markers: Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking. Applications include a method of treating a patient with a pharmaceutically acceptable implant system comprising implanting a collection of pharmaceutically acceptable, covalently-crosslinked hydrogel particles, wherein the collection comprises a plurality of sets of the... Agent: Incept, LLC
20140056821 - Nanoparticulate compositions for diagnostic imaging: wherein R1 is independently at each occurrence a C1-C3 alkyl group; R3 is independently at each occurrence a hydrogen or a C1-C3 alkyl group; R4 is a C1-C5 aliphatic radical, a C7-C12 aromatic radical, or a C5-C10 cycloaliphatic group; n is 0, 1, 2 or 3; q is 1, 2... Agent: General Electric Company
20140056817 - Photodynamic therapy or diagnostic agent, using infrared-spectrum light: It is intended to provide a therapeutic and/or diagnostic agent that can be used in photodynamic therapy (PDT) or photodynamic diagnosis (PDD) capable of utilizing infrared-spectrum light such as near-infrared light (NIR), infrared light, or far-infrared light, which attains a deep body penetration. The present invention provides a photodynamic therapeutic... Agent: Tokyo Institute Of Technology
20140056818 - Process for delivering encapsulated neutral bioimaging molecules, complex, and process thereof: The present disclosure relates to delivering neutral bioimaging molecules encapsulated within icosahedral DNA capsules in vivo and in vitro. The present disclosure also discloses the entrapment of neutral bioimaging molecules like FITC dextran within the cavity of a DNA polyhedron without any molecular recognition or chemical conjugation between host (DNA... Agent: National Centre For Biological Sciences
20140056824 - Ionic complexes: The present invention provides a phosphopeptide or phosphoprotein (PP) stabilised amorphous calcium phosphate or amorphous calcium fluoride phosphate complex having a calcium ion greater than about 30 moles of calcium per mole of PP.... Agent: The University Of Melbourne
20140056825 - Functional fragrance precursor: The present invention relates to a class of fragrance precursor compounds comprising one or more of the compounds derived from the reaction of X—OH and an aldehyde or ketone, said fragrance precursor compounds being of the formula X—O—C(R)(R*)(OR**) wherein R is a C6-24 alkyl group, a C6-24 aralkyl group or... Agent: Colgate-palmolive Company
20140056826 - Functional fragrance precursor: The present invention relates to a class of fragrance precursor compounds comprising one or more of the compounds derived from the reaction of X—OH and an aldehyde or ketone, said fragrance precursor compounds being, of the formula X—O—C(R)(R*)(OR**) wherein R is a C6-24 alkyl group, a C6-24 aralkyl group or... Agent: Colgate-palmolive Company
20140056827 - Dental composition: Aqueous homogeneous oral care compositions including a fluoride salt and unfunctionalised β-tricalcium phosphate, characterised in that β-tricalcium phosphate is present in a catalytic and fluoride-stable amount relative to the fluoride salt. Such compositions are of use in combating dental caries, dental erosion and/or tooth wear.... Agent:
20140056830 - Method of producing a safe, whole-extract of curcuma for oral and topical use: Methods of making safe extracts of Curcuma longa L. are provided. The processes provided include methods that use an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. The processes can produce a significantly higher yield from a single... Agent: California Northstate College Of Pharmacy, LLC
20140056828 - Novel formulations and uses for curcuma extracts: Formulations and uses of extracts of Curcuma longa L. plants for safe use topically, orally, rectally, or vaginally, for example, are provided. A sunscreen containing an extract of Curcuma longa L. is provided, the sunscreen having an absorption that spans the UVA and UVB ranges in a manner that meets... Agent:
20140056829 - Sunscreen comprising a curcuma extract: Sunscreen compositions containing an extract of Curcuma longa L. are provided, the sunscreens having an absorption that spans the UVA and UVB ranges in a manner that meets updated FDA recommendations without requiring the addition of titanium dioxide. The sunscreens can also include an extraction solvent that is at least... Agent: California Northstate College Of Pharmacy, LLC
20140056831 - Treatment and reduction in incidence of skin cancer: A method for treatment of skin cancer in tissue within the skin of a mammal uses the ingestion, injection, infusion or application of an ingredient having a pharmaceutically active phenyl boric acid or salts of a phenyl boric acid to treat the affected tissue. The treatment may be with an... Agent:
20140056832 - Use of a 2-methylsuccinic acid diester derivative as solvent in cosmetic compositions; cosmetic compositions containing the same: The present invention relates to the use of at least one 2-methylsuccinic acid diester derivative of formula (I), in a composition comprising, in a cosmetically acceptable medium, at least one liquid fatty phase and at least one lipophilic active agent, for dissolving the said active agent in the said liquid... Agent:
20140056833 - Compositions and methods for nail coatings: The present disclosure relates generally to compositions for natural and artificial nail coatings, and particularly, but not by way of limitation, to polymerizable compositions and adhesion-promoting basecoats polymerized therefrom. The disclosure further relates to methods of making a polymerized basecoat that are more easily removed than artificial nail enhancements and... Agent: Creative Nail Design, Inc.
20140056834 - Cosmetic composition comprising chrysophanol as active ingredient for skin whitening: A novel use of chrysophanol for skin whitening is provided, in which chrysophanol is included in a cosmetic composition as an effective ingredient for skin whitening. The chrysophanol compound has excellent stability and can also effectively inhibit melanin production via mechanism of inhibiting expression and activity of tyrosinase.... Agent: Pukyong National University Industry-university Cooperation Foundation
20140056835 - Cosmetic composition for skin whitening comprising small molecule-peptide conjugate: The present invention relates to a cosmetic composition for skin whitening comprising a small molecule-peptide conjugate. More specifically, it concerns the cosmetic composition for skin whitening comprising Caffeic acid-LG-NH2 or Coumaric acid-LG-NH2 as an active ingredient, which inhibits tyrosinase activity and melanin production, thereby showing an excellent skin whitening effect,... Agent: Ae Kyung Industrial Co., Ltd.
20140056836 - Spray-dried compositions and their uses: The present invention relates to spray dried compositions of one or more active ingredients dispersed in a carrier of gum Arabic in admixture with a non-ionic surfactant. The compositions are particularly useful for the encapsulation of menthol and can be used to prepare chewing gums and compressed tablets.... Agent: Firmenich Sa
20140056837 - Compositions and methods for control of malodor and other environmental contaminants: Nanocomposite compositions forming mixed clathrates and methods for using such compositions for entrapping guest moieties such as malodors, molds and cells are disclosed.... Agent:
20140056838 - Recreational water with improved interaction with skin, hair and eyes: The feel of skin and hair and the manageability of hair exposed to recreational water is improved by the addition of select organic polymers, e.g., charged organic polymers such as cationic organic polymers containing multiple charges. In one embodiment, excellent results are achieved when the added organic polymer(s) include polymeric... Agent: Chemtura Corporation
20140056839 - Methods for sealing wounds with a sterilized composition of a cyanoacrylate monomer and a poloxamer: The present invention relates to compositions of cyanoacrylate monomer, a method of improving the viscosity and the curing speed with a single additive and a process of providing sterilized cyanoacrylate adhesive compositions for application in the medical field.... Agent: Adhezion Biomedical, LLC
20140056841 - Compositions and methods for promoting the healing of tissue of multicellular organisms: Compositions are provided for promoting healing of tissue of a vertebrate organism. The compositions can be for internal administration of a therapeutically effective amount of pharmacologically active, protease inhibiting, aqueous media soluble polysulfonated materials in salt form and associated with a secondary material to reduce one or more of inflammation,... Agent:
20140056840 - Hindered alkylamine polymer: The present invention relates to a polymer comprising hindered primary amine groups bonded to the backbone of the polymer by way of an amide, ester, or thioester linkage. The polymer is particularly useful as an adjuvant, especially for isothiazolone, and as a dispersant and stain blocker in coatings formulations.... Agent: Dow Global Technologies LLC
20140056842 - Cellular therapeutic approaches to traumatic brain and spinal cord injury: The described invention provides cellular therapeutic approaches for treating a vascular insufficiency following a traumatic injury to head or spine that results in an injury to brain, spinal cord, or both by administering a therapeutic amount of an isolated, nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+... Agent:
20140056843 - Tnfsf single chain molecules: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.... Agent: Apogenix Gmbh
20140056845 - Method for generating potent dendritic cells: Highly potent dendritic cells are generated in vivo or ex vivo by exposing precursor cells to an effective dose of IL-32.... Agent: The Regents Of The University Of California
20140056844 - Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer: Methods for treating cancer comprising administering a metabolic targeting chemo-immunotherapy regimen are provided herein. In one embodiment, the metabolic targeting chemo-immunotherapy regimen may include steps of administering a therapeutically effective dose of one or more immunologic agents (e.g., a therapeutic antibody) to stimulate an immune response in a subject having... Agent:
20140056846 - Treating hepatitis c virus infection: Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HCV release from the cell. The methods can be used to decrease serum viremia of an HCV-infected person.... Agent: Board Of Regents, University Of Texas System
20140056847 - Inhibitors of serine proteases: t
20140056848 - Method for the treatment of multiple sclerosis: A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of 2ME2 or a derivative thereof.... Agent: Entremed, Inc.
20140056849 - Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use: The present invention provides substituted azaindole prodrugs, methods of making said prodrugs, pharmaceutical compositions of said prodrugs and methods of using said prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer.... Agent: Calitor Sciences, LLC
20140056850 - Dictyostelid amoeba and biocontrol uses thereof: The present invention relates to Dictyostelids myxamoebae of phylum Mycetozoa and uses thereof. In particular, the present invention relates to the use of amoebae, slugs, or their environmentally stable spores to treat microbial infections and other uses.... Agent: Amebagone, LLC
20140056851 - Methods for managing weight loss and body mass: The invention provides methods for promoting weight loss by an animal, promoting weight loss by an animal while preventing or minimizing loss of lean body mass by the animal preventing a reduction in energy metabolism by an animal reducing the risk of regaining weight by an animal after weight loss,... Agent: Nestec Sa
20140056860 - Method for rejuvenating cells: The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stem cells (iPSCs) from a target cell population comprising cells from aged... Agent: Universite Montpellier I
20140056861 - Recombinant factor viii having increased stability: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates... Agent: University Of Rochester
20140056852 - Bifidobacterium bifidum strains for application in gastrointestinal diseases: The present invention provides a strain of Bifidobacterium bifidum or mutant or variant thereof showing at least an adhesion of about 10 bacterial cells per mm2 of epithelial cell monolayer or having at least an adhesion index of 1.5 and a strain of Bifidobacterium bifidum or mutant or variant thereof... Agent: Naturwohl Pharma Gmbh
20140056853 - Compositions and methods for modulating plant parasitic nematodes: Provided is a method for modulating soybean cyst nematode infestation of a plant comprising applying to the plant an effective amount of a composition comprising a Chromobacterium, Burkholderia, and/or Flavobacterium strain to modulate the soybean cyst nematode infestation. The composition may be applied directly to the seed or in a... Agent: Marrone Bio Innovations, Inc.
20140056862 - Nutritional compositions having alpha-hica and alpha-ketoglutarate: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality... Agent: Nestec S.a.
20140056863 - Nutritional compositions having alpha-hica and eicosapentaenoic acid: Nutritional compositions for maximizing muscle protein synthesis while minimizing the catabolism of muscle proteins and methods of using same are provided. In this manner, the nutritional compositions may provide for retention of lean body mass, which helps to avoid loss of independence and functionality, as well as to improve quality... Agent: Nestec S.a.
20140056864 - Bacillus isolates and methods of their use to protect against plant pathogens and virus transmission: Methods of inducing systemic acquired resistance to infection in a plant are provided. The methods comprise applying a composition comprising a Bacillus control agent to said plant wherein said plant is capable of producing defense proteins. Also provided are, methods for controlling one or more plant diseases, methods for preventing... Agent: Montana State University
20140056866 - Use of biological or chemical control agents for controlling insects and nematodes in resistant crops: The present invention relates generally to the use of biological or chemical control agents with for controlling insects and nematodes and to methods particularly useful for combating insects or nematodes and/or increasing crop yield in plants that are at least partially resistant to one or more parasitic nematodes or insects.... Agent: Bayer Intellectual Property Gmbh
20140056854 - Viral vectors with modified transduction profiles and methods of making and using the same: The present invention provides AAV capsid proteins, virus capsids comprising said capsid proteins and virus vectors comprising said capsid proteins, wherein the AAV capsid proteins have one or more mutations, wherein the mutation(s) result in a phenotype of decreased liver transduction and/or reduced glycan binding affinity as compared to a... Agent: The University Of North Carolina At Chapel Hill
20140056857 - Cancellous bone treated with collagenase and essentially free of blood cells: A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic... Agent:
20140056858 - Cell sheet having hyaluronic acid production ability and method for preparing the same: A cell sheet having a high hyaluronic acid production ability can be typically prepared by a method in which, on a cell culture support having a surface coated with a polymer which changes a hydration ability in a temperature range of 0-80° C., cells with increased stem cell content are... Agent: Cellseed Inc.
20140056856 - Immunosuppressive cells and methods of making and using thereof: This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine.... Agent: National Health Research Institutes
20140056855 - Llp2a-bisphosphonate conjugates for osteoporosis treatment: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the... Agent: The Regents Of The University Of California
20140056859 - Method for producing myocardial sheet from embryonic stem cells: The present invention provides a method for producing a myocardial sheet using a group of cells derived from embryonic stem cells. This method is characterized by mixing Flk/KDR positive cells, cardiomyocytes, endothelial cells, and mural cells, all derived from embryonic stem cells, and culturing the mixed cells. Furthermore, the myocardial... Agent: Tokyo Woman's Medical University
20140056865 - Adipose composition systems and methods: Embodiments of the present invention encompass compositions containing an adipose derived carrier, matrix, or filler, in some cases optionally in combination with bone particles or other granular materials or substances, for delivery to a human patient. Methods of manufacture and use of such adipose derived compositions are also disclosed.... Agent: Allosource
20140056867 - Targeted therapeutic proteins: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor.... Agent: Biomarin Pharmaceutical
20140056869 - Compositions and methods for enhancing metal ion dependent drug therapies: Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for... Agent: CnssIPHoldings, Inc.
20140056868 - Supercoiled minivectors as a tool for dna repair, alteration and replacement: In some embodiments the present disclosure provides a composition for targeted alteration of a DNA sequence and methods of altering the targeted DNA sequence using the composition. In some embodiments such a composition comprises a MiniVector comprising a nucleic acid sequence template for homology-directed repair, alteration, or replacement of the... Agent: Baylor College Of Medicine
20140056870 - Fusion proteins: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which cleaves a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin Targeting Moiety that binds a Binding Site on the nociceptive sensory afferent, which can undergo endocytosis to be incorporated into an endosome; a protease... Agent: Syntaxin Limited
20140056871 - Anti-inflammatory antibodies and uses therefor: The invention provides antibodies that inhibit activation of complement, which may be used to treat various inflammatory diseases or disorders.... Agent: Decimmune Therapeutics, Inc.
20140056872 - Antagonists of neuropilin receptor function and use thereof: The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.... Agent: Children's Medical Center Corporation
20140056887 - Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.... Agent: Biogen Idec Inc.
20140056889 - Compositions and method for treating autoimmune diseases: The invention provides methods and compositions for treating various autoimmune diseases (such as systemic lupus erythematousu) with an interferon inhibitor (such as an anti-intereron-alpha monoclonal antibody). More specifically, the invention provides a method of diagnosing, monitoring and adjusting the treatment of such a patient by way of an interferon signature... Agent: Genentech, Inc.
20140056879 - Fc variants that extend antibody half-life: The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.... Agent: Xencor, Inc.
20140056888 - High concentration antibody formulations: The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component C5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using... Agent: Alexion Pharmaceuticals, Inc.
20140056886 - Humanized anti-il-20 antibody and uses thereof: Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.... Agent: National Cheng Kung University
20140056878 - Humanized antibodies directed against complement protein c5: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to complement protein C5. The invention provides a C5-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention provides an isolated complement protein C5... Agent:
20140056881 - Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-postitive and her2-positive subtypes with clinical implications: A method to determine the clinical outcome of breast tumour affecting a patient if treated with an antitumoural agent against breast tumour, the said method comprising the step of assaying a sample of a breast tumour from said patient for an expression level of selected genes, by contacting mRNA sequences... Agent: Universite Libre De Bruxelles
20140056874 - Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapy: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.... Agent: Hoffmann-la Roche Inc.
20140056875 - Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapy: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.... Agent: Hoffmann-la Roche Inc.
20140056876 - Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapy: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.... Agent: Hoffmann-la Roche Inc.
20140056873 - Methods for treating conditions associated with masp-2 dependent complement activation: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2... Agent: Omeros Corporation
20140056877 - Stabilized liquid anti-rsv antibody formulations: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof,... Agent: Medimmune, LLC
20140056883 - Subcutaneously administered anti-il-6 receptor antibody: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of... Agent: Hoffmann-la Roche Inc.
20140056884 - Subcutaneously administered anti-il-6 receptor antibody: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of... Agent: Hoffmann-la Roche Inc.
20140056885 - Subcutaneously administered anti-il-6 receptor antibody: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of... Agent: Hoffmann-la Roche Inc.
20140056882 - Treatment of pulmonary disease conditions: The present invention relates generally to a method for treating or preventing or otherwise ameliorating the effects of pulmonary diseases characterized by or associated with infiltration of neutrophils and complications arising therefrom. The present invention further provides agents and pharmaceutical compositions comprising agents which inhibit the activity of G-CSF or... Agent: Csl Limited
20140056880 - Triazole compounds as ksp inhibitors: as further described herein. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, and a method of treating a disorder mediated, at least in part, by KSP in a mammalian patient comprising administering to a mammalian patient in need of such... Agent: Novartis Ag
20140056890 - Binding agents that modulate the hippo pathway and uses thereof: The present invention relates to agents that modulate the Hippo pathway and Hippo pathway signaling, such as antibodies and soluble receptors, as well as to methods of using the agents for the treatment of diseases such as cancer.... Agent:
20140056893 - Homodimeric proteins: This present invention relates to a homodimeric protein comprising fibroblast growth factor 21 (FGF21) and glucagon-like peptide (GLP-1), pharmaceutical compositions comprising the homodimeric protein, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such homodimeric protein.... Agent: Eli Lilly And Company
20140056891 - Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins: The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be... Agent: Five Prime Therapeutics, Inc.
20140056892 - Vista-ig for treatment of autoimmune, allergic and inflammatory disorders: The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig). The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune... Agent:
20140056894 - Rspondins as modulators of angiogenesis and vasculogenesis: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2... Agent: Deutsches Krebsforschungszentrum Stiftung Des Offentlicen Rechts
20140056896 - Anti-cd19 antibodies and uses in b cell disorders: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC.... Agent: Duke University
20140056899 - Anti-her antibodies: The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.... Agent: Genentech, Inc.
20140056897 - Bispecific three-chain antibody-like molecules: The present invention relates to novel bispecific three-chain antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific three-chain antibody-like molecules (TCAs) capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.... Agent: Hco Antibody, Inc.
20140056898 - Combination therapies comprising anti-erbb3 agents: Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering either i) an effective amount of an anti-estrogen agent or ii) an effective amount of a receptor tyrosine... Agent:
20140056895 - Dual variable region antibody-like binding proteins having cross-over binding region orientation: The invention provides antibody-like binding proteins comprising four polypeptide chains that form four antigen binding sites, wherein each pair of polypeptides forming an antibody-like binding protein possesses dual variable domains having a cross-over orientation. The invention also provides methods for making such antigen-like binding proteins.... Agent: Sanofi
20140056907 - Anti-asic1 antibodies and uses thereof: The present invention provides antibodies and antigen-binding fragments thereof that specifically bind to cells expressing acid-sensing ion channel-1 (ASIC1). According to certain embodiments of the invention, the antibodies inhibit acid-induced, ASIC1-mediated ion currents in cells expressing human ASIC1. According to certain embodiments, the antibodies of the invention are selective for... Agent: Regeneron Pharmaceuticals, Inc.
20140056905 - Anti-kit antibodies and uses thereof: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit... Agent: Kolltan Pharmaceuticals, Inc.
20140056901 - Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies: The disclosure provides antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes). The antibodies may be used to treat tauopathies (e.g. Alzheimer's disease).... Agent:
20140056904 - Antibodies to ttr and methods of use: The disclosure pertains to antibodies and binding fragments thereof that specifically binds all or part of EHAEVVFTA. Also provided are isolated peptides, isolated nucleic acids, immunogens, compositions, immunoassays and kits and method of using said reagents to detect misfolded TTR.... Agent: University Health Network
20140056903 - Human antibodies to gfr alpha 3 and methods of use thereof: The present invention provides antibodies that bind to human GFRα3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GFRα3. The antibodies of the invention are useful for the treatment of diseases and disorders associated with one... Agent: Regeneron Pharmaceuticals, Inc.
20140056900 - Method for inhibiting binding to b-cell receptor: The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprises: i) a polypeptide having the amino acid sequence of figure (1); or ii) a variant of the polypeptide of i).... Agent: Glaxo Group Limited
20140056902 - Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia: The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the... Agent: Kyowa Hakko Kirin Co., Ltd
20140056906 - Secreted proteins: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.... Agent: Incyte Corporation
20140056908 - Closterovirus-based nucleic acid molecules and uses thereof: The present invention relates to novel nucleic acid molecules for producing target polypeptides in plant cells. More specifically, the novel nucleic acid molecules comprise a minireplicon derived from a Closteroviridae virus and heterologous polynucleotides encoding the target polypeptides. Also provided are compositions comprising the target polypeptides and uses thereof.... Agent: Fraunhofer Usa Inc.
20140056911 - Breast endothelial cell expression patterns: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that... Agent: The Johns Hopkins University
20140056912 - Methods of treating squamous cell carcinoma: The disclosure relates to methods for treating a sclerostin-expressing cancer, e.g., a squamous cell carcinoma (SCC), e.g., SCC of the upper aerodigestive tract, esophagus, or lung, employing a therapeutically effective amount of at least one sclerostin antagonist, e.g., an anti-sclerostin antibody, such as Antibody 1, 2, 3, 4 or 5.... Agent: Novartis Ag
20140056910 - Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as... Agent: Kringle Pharma Inc.
20140056909 - Treating cancer: This document relates to methods and materials involved in treating cancer (e.g., melanoma). For example, methods and materials involved in using an anti-chronic inflammation treatment (e.g., chemotherapy) in combination with a cancer treatment agent (e.g., a cancer vaccine) to treat cancer are provided.... Agent: Mayo Foundation For Medical Education And Research
20140056913 - Anti-dengue virus antibodies and uses thereof: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of... Agent: Massachusetts Institute Of Technology
20140056914 - Human cytomegalovirus neutralising antibodies and use thereof: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes... Agent: Institute For Research In Biomedicine
20140056916 - Aldosterone induced vascular elastin production: Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.... Agent: Human Matrix Sciences, LLC
20140056917 - Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death: Disclosed herein are methods and compositions comprising fingolimod and anti-CD74 antibodies or fragments thereof. In preferred embodiments, the fingolimod increases the expression of CD74 in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 antibodies. The compositions and methods are of use to... Agent: The Ohio State University
20140056915 - High affinity antibody antagonists of interleukin-13 receptor alpha 1: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody... Agent: Csl Limited
20140056919 - Methods and compositions for treating inflammatory conditions: The present invention is directed to methods of treating an inflammatory condition in a patient. This method includes providing a therapeutic agent that is a vascular endothelial growth factor receptor-3 (VEGFR-3) agonist or a nucleic acid molecule encoding a VEGFR-3 agonist. The present invention is further directed to pharmaceutical compositions... Agent: University Of Rochester
20140056918 - Oscar antagonists: The present invention relates to antagonistic OSCAR ligands. The present invention furthermore relates to use of such ligands.... Agent:
20140056920 - Methods for treating or preventing asthma by administering an il-4r antagonist: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.... Agent: Sanofi
20140056921 - Hepatocyte growth factor receptor antagonists and uses thereof: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions,... Agent: Genentech, Inc.
20140056922 - Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune... Agent: The United States Of America,as Represented By The Secretary, Department Of Health And Human Service
20140056923 - Method of treating hypertension disorder and a pharmaceutical agent: Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a... Agent:
20140056924 - Glp-1 receptor agonist compounds for obstructive sleep apnea: The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1(7-37), GLP-1(7-37) analogs (e.g., GLP-1(7-36)-NH2) and the like. The GLP-1 receptor agonist compound may be exenatide.... Agent: Amylin Pharmaceuticals, LLC
20140056925 - Methods of reducing myocardial injury following myocardial infarction: The present invention discloses methods of reducing injury resulting from cardiovascular disease, such as myocardial infarction, and/or promoting myocardial repair. The methods include administering an ephrin and pharmaceutical compositions including ephrins to a subject. Kits useful for accomplishing the same are also provided.... Agent: East Carolina University
20140056926 - Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof: The present invention relates to a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine, and a use of the complex. The complex according to the present invention may be used as an analysis tool in an in vitro biological assay method,... Agent: Snu R&db Foundation
20140056931 - Genetic adjuvants for immunotherapy: The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions... Agent: University Of South Florida
20140056929 - Immunomodulation by controlling interferon-gamma levels with the long non-coding rna nest: Compositions and methods of modulating an immune response by controlling levels of interferon-gamma (IFN-γ) production by leukocytes are disclosed. Adjustment of IFN-γ levels is achieved by increasing or decreasing the activity of NeST (nettoie Salmonella pas Theiler's [cleanup Salmonella not Theiler's]), a long non-coding RNA that induces expression of IFN-γ.... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20140056927 - Lipotheichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria: The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as... Agent: Nestec S.a.
20140056928 - Novel compounds: wherein R1 is n-C1-6alkyl or C1-2alkoxyC1-2alkyl-, R2 is halo, OH or C1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or... Agent: Glaxosmithkline LLC
20140056930 - Using pomegranate extracts for increasing prostate specific antigen doubling time: A method of increasing a prostate specific antigen (PSA) doubling time in treating a patient. A subject with rising serum PSA is selected. A composition is administered to the subject comprising a therapeutically effective amount of a pomegranate extract comprising a higher content of high molecular weight polyphenol compared to... Agent: Pom Wonderful, LLC
20140056932 - Polynucleotides encoding mhc class i-restricted htert epitopes, analogues thereof or polyepitopes: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also... Agent: Institut Pasteur
20140056934 - Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a: The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.... Agent: Glaxosmithkline Biologicals Sa
20140056933 - Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity: The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house... Agent:
20140056935 - Peptide which can induce antibody capable of recognizing stereostructure of hiv: An object of the present invention is to provide a peptide capable of inducing a superior or new neutralizing antibody against HIV, so that HIV infectious disease can be prevented and treated or a greater variety of preventive or therapeutic options can be offered. This object is achieved by using... Agent: National University Corporation Tokyo Medical And Dental University
20140056936 - Compositions and methods using recombinant mhc molecules for the treatment of stroke: Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and... Agent: Oregon Health & Science University
20140056937 - Warm sensation recovery lotion and method for manufacturing the same: A kind or warm sensation recovery lotion and a method for manufacturing the same are revealed. Firstly mix a warming agent derived from vanillyl butyl ether (VBE) and a surface active agent derived from hydrogenated castor oil, zingiber officinale (ginger) root extract and plant extracts. Then add water as a... Agent: Well Max Beauty Lab Co., Ltd.
20140056938 - Alphavirus compositions and methods of use: Embodiments are directed compositions related to Eilat virus and uses thereof.... Agent: The Board Of Regents Of The University Of Texas System
20140056939 - Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination: We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and... Agent: Vrije Universiteit Brussel
20140056940 - Novel adjuvant compositions: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the... Agent:
20140056941 - Antigenic formulation: The present invention pertains to an antigenic formulation comprising a biological antigen, wherein the formulation comprises an oil containing as a principle constituent a fatty acid ester of eleostearic acid. The invention also pertains to the use of the said oil to manufacture an antigenic formulation.... Agent:
20140056942 - Liquid stable virus vaccines: The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.... Agent:
20140056943 - Immuno-stimulant combination for prophylaxis and treatment of hepatitis c: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use... Agent: Proyecto De Biomedicina Cima, S.l.
20140056944 - Isolation of lymphocytes and delivery to splenectomy patients: The present invention includes a method and device for the isolation of lymphocytes, particularly splenic lymphocytes, for administration to patients. In particular for patients undergoing a splenectomy, administration of splenic lymphocytes may increase a patient's immunity and reduce the likelihood of post-splenectomy infections and other complications.... Agent: Children's Hospital Of Orange County
20140056946 - Method for isolation of polysaccharides: e
20140056949 - Controlled release mucoadhesive systems: Formulations for chemoprevention of oral cancer and precancerous lesions, and for methods for preparing the formulations are described.... Agent: The Ohio State University
20140056953 - Fatty acid acylated amino acids for oral peptide delivery: The present invention relates to fatty acid acylated amino acids (FA-aa's) acting as permeation enhancers for oral delivery of therapeutic macromolecules such as peptides and pharmaceutical compositions comprising such FA-aa's.... Agent: Novo Nordisk A/s
20140056948 - Hard tissue regeneration material and method for manufacturing the same: A hard tissue regeneration material and a method for manufacturing the same are disclosed. The hard tissue regeneration material of the present invention comprises: ZnO particles selected from the group consisting of crystallized ZnO particles, crystallized ZnO nanorods, nano-ZnO hollow fibers, and a combination thereof; and at least one selected... Agent: National Cheng Kung University
20140056952 - Methods and coatings for treating biofilms: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described.... Agent: President And Fellows Of Harvard College
20140056951 - Methods and compositions for treating biofilms: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described.... Agent: President And Fellows Of Harvard College
20140056950 - Tricalcium phosphates, their composites, implants incorporating them, and methods for their production: Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are... Agent: Pioneer Surgical Technology, Inc.
20140056947 - Virus traps: Specific applications of particles and particle agglomerates with semiconductor surfaces are provided. The particles and particle agglomerates display a high affinity for viral particles, and may be used therapeutically and/or prophylactically to treat or prevent viral infections. The particles and particle agglomerates may also be used to remove viral particles... Agent: Universitatsklinikum Schleswig-holstein
20140056954 - Multicomponent glasses for use in personal care products: The present invention relates to multicomponent glasses and their use in powdered form as an additive in personal care products such as toothpastes.... Agent:
20140056955 - Powderous vitamin e formulations: The present invention relates to improved vitamin E formulations, as well as to the production of such formulations.... Agent: DsmIPAssets B.v.
20140056956 - Coating compositions for pathogen control in monocotyledonous plants: Coating composition for applying to a plant structure of a monocotyledonous plant from which roots and shoots are capable of growing, wherein the said coating composition comprises an organic carrier material and one or more biological agents that possess an activity against at least one or more pathogens of the... Agent: Exosect Limited
20140056957 - Extended production of nitric oxide from microencapsulated chemical reactants: Methods and compositions are provided for generating and applying long-lasting therapeutic nitric oxide (NO) gas from the reaction of water-soluble chemical reactants microencapsulated in polymer matrices. In some applications the microencapsulated reactants are introduced in an aqueous gel, and in other applications they are introduced to the area of therapy... Agent: Nioxx LLC
20140056958 - Apparatus, system, and method for creating biologically protected/enhanced spaces in vivo: The present invention creates a biologically protected or enhanced space in vivo in a mammal to allow the mammal's immune system and/or other biological processes to function properly in order to treat autoimmune diseases. In particular, the biologically protected/enhanced space allows biological processes to occur that can therapeutically treat Type... Agent:
20140056960 - Methods for improving fracture healing and bone formation: The invention provides a method of promoting bone formation in a patient at a site in need thereof, the method comprising the step of locally administering a pro-inflammatory compound to the site, wherein the pro-inflammatory compound is selected from one or more of TNF-α at optimal osteogenic dose of 0.5... Agent: Imperial Innovations Limited
20140056959 - Nucleic acid aptamers: The present invention relates to optimized aptamers and methods of using these aptamers.... Agent: University Of Iowa Research Foundation
20140056962 - Drug delivery system: The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first... Agent: Merck Sharp & Dohme B.v.
20140056961 - Platinum-catalyzed intravaginal rings: The present invention provides improved intravaginal drug delivery devices, i.e., intravaginal rings, useful for the prophylactic administration of an antimicrobial compound, e.g., Dapivirine, to a human. The intravaginal rings of the invention address previous stability issues by utilizing a platinum catalyst (e.g., in the form of a platinum-siloxane complex) for... Agent: International Partnership For Microbicides
20140056963 - Extended production of nitric oxide from a microencapsulated nitrite salt and an aqueous acidified gel: Methods and compositions are provided for generating and applying long-lasting therapeutic nitric oxide (NO) gas from the reaction of a least one microencapsulated nitrite salt and an activating volume of an aqueous acidified gel that has sufficient acidity to convert the nitrite salt to a nitric oxide (NO) and further... Agent: Nioxx LLC
20140056964 - Granzyme b inhibitor compositions, methods and uses for promoting wound healing: Methods of promoting wound healing in a subject is disclosed. The method include applying a Granzyme B (Granzyme B) inhibitor to the wound. The wound may be a skin wound. The Granzyme B inhibitor may be comprised of nucleic acids, or peptides, including but not limited to antibodies, or small... Agent: The University Of British Columbia
20140056965 - Method and system for treating depression or epilepsy: A removable patch configured to be applied over a skin surface, comprises an adhesive layer disposed on the removable patch, and a delivery layer disposed on the removable patch. The delivery layer carries an activating chemical neuromodulator adapted to be transcutaneously applied to afferent A fibers disposed under the skin... Agent: Boston Scientific Neuromodulation Corporation
20140056972 - Anti-dclk1 monoclonal antibodies and methods of production and use thereof: Monoclonal antibodies against DCLK1 and conjugates containing these monoclonal antibodies are disclosed. Methods of producing and using these monoclonal antibodies are also disclosed.... Agent: The Board Of Regents Of The University Of Oklahoma
20140056969 - Compositions and methods for sirna inhibition of angiogenesis: RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types... Agent:
20140056966 - Conjugate angiostation or its fragment, the method of producing the conjugate and use thereof: The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as... Agent: Protgen Ltd.
20140056971 - Delivery of ibuprofen and other compounds: The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and... Agent: Strategic Science & Technologies, LLC
20140056970 - Efficient method for loading amphoteric liposomes with nucleic acid active substances: A method for preparing amphoteric liposomes loaded with a polyanionic active agent as cargo, characterised by admixing an aqueous solution of said polyanionic active agent and an alcoholic solution of one or more amphiphiles and buffering said admixture to an acidic pH, said one or more amphiphiles being susceptible of... Agent: Marina Biotech, Inc.
20140056968 - Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it: The subject of the present invention is a liposomal formulation containing an anti-tumour compound characterised in that it contains the active compound encapsulated in liposome vesicles forming a composition of lipid components in the ratio of 1 part by mass of the active compound per 5 parts by mass of... Agent: Wroclawskie Centrum Badan Eit+ Sp Z O.o.
20140056967 - Vaccines against chlamydial infection: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.... Agent: Corixa Corporation
20140056973 - Oral dosage forms having a high loading of a methyl hydrogen fumarate prodrug: Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.... Agent: Xenoport, Inc.
20140056975 - Pharmaceutical composition: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from... Agent: Alpharma Pharmaceuticals LLC
20140056974 - Spontaneously dispersible n-benzoyl staurosporine compositions: Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.... Agent: Novartis Ag
20140056976 - Methods and compositions for heavy metal removal and for oral delivery of desirable agents: Compositions and methods for heavy metal remediation are disclosed. The compositions contain ceramic nanoparticulate cation exchangers specific for at least one heavy metal as well as at least one carrier, typically a thickener, a gel forming agent and/or a cross-binding agent. The compositions may also contain chelating agents as well... Agent:
20140056978 - Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed.... Agent: Xenoport, Inc.
20140056977 - Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof: The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound.... Agent: Ipsen Pharma S.a.s.
20140056979 - Controlled release pharmaceutical dosage forms: The present invention relates to pharmaceutical multilayer dosage forms, for example to a tamper resistant dosage form comprising a first layer comprising an active agent and a second layer not comprising said active agent, and processes of manufacture, uses, and methods of treatment thereof providing essentially zero order release.... Agent: Purdue Pharma L.p.
20140056980 - Delayed release drug formulation: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer... Agent: Tillotts Pharma Ag
20140056982 - Enhanced carriers for the delivery of microparticles to bodily tissues and fluids: Improved compositions for tissue augmentation are provided. These compositions comprise an amount of crosslinked material sufficient to provide a melt temperature (Tm) greater than 37 C, wherein microparticles can be substantially uniformly dispersed and maintained at ambient room temperature as well as body temperature. Said compositions also provide high shear... Agent:
20140056981 - Method for producing drug-loaded polymeric nanoparticles by polymerization in presence of drugs: A method for producing drug-loaded polymeric nanoparticles, which includes the steps of: (a) preparing a first solution by dissolving a drug in a polymerizable monomer; (b) preparing a micellar solution by dissolving a surfactant and a water-soluble radical initiator in water; (c) adding said first solution to said micellar solution... Agent: Centro De Investigacion En Quimica Aplicada
20140056983 - Food additive for ruminants based on eugenol and cinnamaldehyde: The invention concerns a composition based on a mixture of eugenol and cinnamaldehyde, as food additive for feeding ruminants. The composition may be incorporated in a food additive or a salt block. The eugenol and the cinnamaldehyde may be natural or identical natural constituents. Administering the composition of the food... Agent: Axis France S.a.s.
20140056985 - Method for production of particles of pharmaceutical substances and the use thereof: The invention relates to a method for producing particles with a length-width ratio of less than about 1.4 from a pharmaceutical substance, which method includes the following stages, that is: (a) provision of a melt of the pharmaceutical substance; (b) production of droplets of the melt by spraying into a... Agent: Glatt Gmbh
20140056984 - Modified release formulations containing drug-ion exchange resin complexes: An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix.... Agent: Tris Pharma, Inc.
20140056986 - Methods of treating bladder cancer: The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise a taxane and an albumin.... Agent: Abraxis Bioscience, LLC
20140056987 - Compositions comprising extracts or fractions derived from annona squamosa for the prevention, treatment or control of inflammatory and metabolic disorders: The invention discloses synergistic composition comprising at least one Annona squamosa derived component standardized to acetogenin compound(s) having α,β-unsaturated-γ-methyl-γ-lactone moiety in combination with at least one biologically active ingredient derived from plants, animals or microorganisms such as vitamins, amino acids, minerals, fibers, various plant and herbal extracts for the prevention,... Agent: Laila Nutraceuticals
20140056988 - Novel inhibitors of arachidonic acid formation: The invention relates to a novel class of inhibitors of arachidonic acid formation that can be useful for treating inflammatory conditions. Specifically, the invention relates to derivatives of sesamol that confer lower toxicity and increased circulatory lifetimes than pure sesamol.... Agent:
20140056989 - Viral inactivated platelet extract, use and preparation thereof: e
20140056990 - Composition for the treatment of migraine headaches and methods thereof: Provided herein formulations of capsaicin for delivery by nasal route and methods of using the formulations for the treatment of migraines and other severe headaches. The formulations described herein contain mucoadhesives to optimize the therapeutic effect of capsaicin by intranasal delivery.... Agent: Vr1, Inc.
20140056991 - Method of modulating fatty acid mobilization and oxidation: Methods of mobilizing fatty acids are disclosed.... Agent:
20140056992 - Suspension of nanoparticles: A method for preparing suspension of inorganic nanoparticles is described herein. The method includes mixing a dispersing medium (102) with a dispersant (104) and a metal oxide powder (106) to form a primary mixture (110), the dispersant (104) being selected based on interaction energy of the dispersant (104) with respect... Agent: Tata Consultancy Services Limited
20140056993 - Composition comprising antimicrobial metal ions and a quaternary cationic surfactant: The present invention relates to an antimicrobial composition suitable for use on skin and wounds comprising a source of an antimicrobial metal ion and a quaternary cationic surfactant.... Agent: Convatec Technologies, Inc.
20140056994 - Fixed-dose association of phytate and zinc: The invention relates to a fixed-dose association of phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said association for... Agent: Universitat De Les Illes Balears
20140056996 - Antitumoral combination comprising cabazitaxel and cisplatin: The present invention relates to a combination comprising cabazitaxel and cisplatin. The present invention relates also to a pharmaceutical composition containing such a combination and to a pharmaceutical kit comprising: (i) a first galenic formulation comprising cabazitaxel; and (ii) a second galenic formulation comprising cisplatin. The invention relates also to... Agent: Aventis Pharma S.a.
20140056995 - Use of compounds isolated from euphorbia neriifolia for treating cancer and/or thrombocytopenia: Novel Uses of small molecules, particularly, triterpenoids and ingol diterpenes isolated from Euphorbia neriifolia, are disclosed herein. The triterpenoids are useful as lead compounds for manufacturing a medicament or a pharmaceutical composition for treating cancer; whereas the ingol diterpenes are useful as lead compounds for manufacturing a medicament or a... Agent: Mackay Memorial Hospital
20140056997 - Use of low molecular weight amino alcohols in ophthalmic compositions: The use of low molecular weight amino alcohols in ophthalmic compositions is described. These compounds have been found to enhance the efficacy of anti-microbial preservatives.... Agent:
20140056998 - System and method for diagnosis and treatment of neuropsychiatric disorders: An assay for a GCH1 allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCH1 gene, alone... Agent: The Research Foundation For Mental Hygiene
20140056999 - Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom: The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack... Agent: Medicinova, Inc.
20140057000 - Prevention or treatment of painful polyneuropathies by administration of an aluminosilicate: The invention relates to the prevention or treatment of painful polyneuropathies caused by toxic agents, i.e. to the prevention, reduction or elimination of the symptoms associated with such polyneuropathies, such as neuropathic pain. The invention provides an aluminosilicate for use in such prevention or treatment, preferably a natural or synthetic... Agent:
20140057001 - Methods of decreasing sebum production in the skin: Provided herein are methods of using gaseous nitric oxide and/or at least one nitric oxide source to or decrease sebum production in the skin of a subject. In some embodiments, the nitric oxide source includes small molecule and/or macromolecular NO-releasing compounds,... Agent: Novan, Inc.
20140057002 - Anti-fatigue composition of plant material and preparation method, use and products thereof: The present invention provides a composition of a plant material with anti-fatigue activity, its preparation method, usage and related products. The said composition is manufactured from the following plant materials: 20-80% from the genus Rhodiola; 10-60% Gynostemma; 10-60% Lycium. The said composition can be used to manufacture health product, food... Agent:
20140057003 - Augmenting cleaning chemicals: Device, system and method for electrochemical generation of a liquid soap by electrolyzing a surfactant in an aqueous carrier in a cathode compartment of an electrolytic cell and electrolyzing an antimicrobial agent in an aqueous carrier in an anode compartment of the electrolytic cell with the compartments separated by a... Agent:
20140057005 - Development of a pytoestrogen product for the prevention or treatment of osteoporosis using red clover: A phytoestrogen blend was developed using a pharmaceutical platform technology to identify the time course of active components and effect time course of these components in the biophase after administration of a red clover extract. This phytoestrogen blend consists of biochanin A, daidzein, equol and genistein. The recommended daily dosage... Agent:
20140057004 - Herbal polypharmaceutical for preventing and treating atherosclerosis: Herbal MDR for the prevention and treatment of atherosclerosis which includes a summary of the genus Gentiana and a summary of the genus Hippocratea, in particular, gentiana lutea and hippocratea excelsa. Comes as a solid, preferably capsules. Herbal composition is obtained by selecting Rhizome and root of Gentiana lutea blending... Agent:
20140057006 - Pharmaceutical compositions for the treatment of warts: The present invention relates to pharmaceutical compositions for the treatment, and especially topical treatment, of warts and the use thereof for the treatment of warts. Specifically, the present invention relates to pharmaceutical compositions for the treatment of warts, comprising: a) 0.1 to 10 weight % dimethicone; b) 5 to 25... Agent: Atp Marketing & Promotion Ag
20140057007 - Food, particularly a beverage for human consumption: Food, particularly a beverage for human consumption, the ingestion of which enhances cognitive processes such as intelligence, memory, creativity and mood, and/or produces energizing effects. Such food is composed of a composition dilutable or diluted in a liquid or semi-liquid solution. The composition includes at least one nootropic substance, preferably... Agent:
20140057008 - Methods of processing extracts of a t. wilfordii hook f. plant: Products derived from the Tripterygium wilfordii Hook F (TwHF) plant in the form of extracts are provided that are useful in preventing, treating, or ameliorating a symptom of an inflammatory disorder or an immune disorder, such as an auto-immune disease. Also provided are methods of freeze-drying a TwHF root and/or... Agent:02/20/2014 > 151 patent applications in 94 patent subcategories.
20140050660 - T-cell redirecting bispecific antibodies for treatment of disease: The present invention concerns compositions and methods of use of T-cell redirecting complexes, with at least one binding site for a T-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a DNL™ complex. More preferably, the complex comprises... Agent: Ibc Pharmaceuticals, Inc.
20140050662 - Prostate specific antigen agents and methods of using same for prostate cancer imaging: The invention provides a family of agents that target the prostate specific antigen, which can be used as imaging agents or therapeutic agents. The agents can be used to image prostate cancer as well as other physiological processes in a subject.... Agent:
20140050663 - Labeled a4b2 ligands and methods therefor: Contemplated compositions and methods are employed to bind in vitro and in vivo to an α4β2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be... Agent: The Regents Of The University Of California
20140050664 - Soy, lentil or extract stabilized, biocompatible gold nanoparticles: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from soy or lentil plant material or a reactive extract thereof of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. The nanoparticles can... Agent: The Curators Of The University Of Missouri
20140050665 - Method for the treatment or prophylaxis of lymphangioleiomyomatosis (lam) and animal model for use in lam research: Treatment of lymphangioleiomyomatosis with the MEK1/2 inhibitor CI-1040 delayed the development of primary tumors and blocked the estrogen-induced lung metastases in treated animals. Such treatment also reduced the number of circulating ELT3 cells and decreased their lung colonization after intravenous injection.... Agent: Fox Chase Cancer Center
20140050668 - Visualization of lipid metabolism: The present invention relates to the field of in vivo determination of enzyme activity. It also allows visualization of organisms, organs, tissues and cells. In particular, the present invention provides a method of in vivo visualization and a composition suitable for in vivo determination and/or visualization of enzyme activity by... Agent: Centrum Fur Angewandte Nanotechnologie (can) Gmbh
20140050670 - Multifunctional nanoparticles: The invention provides a nanoparticle for delivery of therapeutic agents, comprising a polymeric nanosphere and one or more detection agents, said detection agents for use in detecting the location of the nanoparticle. The invention further provides a transfection agent comprising an aforementioned nanoparticle.... Agent: The University Of Western Australia
20140050671 - Theranostic nanoparticle and methods for making and using the nanoparticle: Nanoparticle having a poly(beta-amino ester) coating. The poly(beta-amino ester) coating includes one or more therapeutic agents that can be delivered by the particle and one or more anchoring groups that couple the polymer to the nanoparticle's core surface. In certain embodiments, the poly(beta-amino ester) includes one or more polyalkylene oxide... Agent: University Of Washington Through Its Center For Commercialization
20140050669 - Use of radiographic contrast agents for detecting dental caries: The present invention provides methods of imaging dental tissue. More particularly, the invention relates to a method of imaging dental caries by administering a topical intra-oral composition that provides enhanced radiographic imaging.... Agent: Creighton University
20140050667 - Renal function analysis method and apparatus: A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent... Agent: Pharmacophotonics, Inc. D/b/a Fast Diagnostics
20140050666 - Scavenger receptor uptake for fabry disease enzyme replacement therapy: The present invention relates to a composition comprising a lysosomal enzyme conjugated to a negatively charged scavenger receptor ligand. In some embodiments, the lysosomal enzyme is conjugated to the scavenger receptor ligand by way of a linker. The present invention also relates to a composition comprising lysosomal enzyme encapsulated by... Agent: Research Foundation Of The City University Of New York
20140050672 - Epidermal cooling: In one aspect, an epidermal coolant dispensable by an aerosol container includes a phase change material that changes phase between about 28-degrees and 40-degrees Celsius. The coolant also includes a solvent in which the phase change material is dissolved and a surfactant. The coolant may further include a propellant to... Agent:
20140050673 - Oil-based foamable carriers and formulations: A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses... Agent: Foamix Ltd.
20140050674 - Method for improving penetration or long term adhesion of compositions to dental tissues and compositions usable in said method: This invention concerns a method of improving penetration of compositions to dentin, enamel, dental pulp or cement and dental compositions for restoration or decoration of teeth, for use in pulp medication comprising, for root canal disinfection and/or obturation and for desensitizing. This invention also concerns uses of DMSO for improving... Agent: University Of Oulu
20140050675 - Antioxidant compositions for soft oral tissue and methods of formulation and use thereof: One embodiment of the invention is directed to an oral antioxidant composition including between 0.0001% and 5.0% w/w antioxidant, wherein the antioxidant includes cinnamic acid derivative, tetrahydrocurcuminoids, or phloretin and an orally pharmaceutically acceptable carrier. The composition may have a pH of at least 5.0. According to still further embodiments,... Agent:
20140050680 - Dapsone to treat rosacea: The methods described herein provide treatment of rosacea using topical formulations of dapsone. The methods also provide treatment of rosacea with topical dapsone in combination with other active agents, including metronidazole. The methods avoid negative hematologic side effects, including hemolysis and hemolytic anemia, that are associated with oral administration of... Agent: Allergan, Inc.
20140050676 - Method for treating skin with retinoids and retinoid boosters: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of a combination of retinoid boosters.... Agent: Conopco, Inc., D/b/a Unilever
20140050677 - Personal care and medicinal products incorporating bound organosulfur groups: Personal care products useful for the maintenance of personal appearance and good health and minor treatments that do not require professional health care, as well as products that provide a combination of anti-oxidant, anti-inflammatory, antimicrobial, and anti-aging properties and are suitable for use without a prescription. The products utilize biomembrane... Agent:
20140050682 - Removable color layer for artificial nail coatings and methods therefor: The present disclosure relates to a nail coating system comprising a basecoat, a color layer, and a topcoat. The system of the present disclosure may be applied to natural and/or pre-existing artificial nail coatings. The present disclosure relates generally to compositions for natural and artificial nail coatings, and particularly, but... Agent: Creative Nail Design, Inc.
20140050685 - Existing shampoo/conditioner company product this time with 55% water 45% existing company shampoo/conditioner ingredient solution: Existing Shampoo/Conditioner Company Product this time with 55% Water 45% Existing Company Shampoo Ingredient Solution is disclosed. It takes less time to shampoo and rinse the hair. There is a better chance of the shampoo to penetrate and be distributed through the hair evenly.... Agent:
20140050688 - Hair care compositions: Compositions and methods are disclosed for imparting a long-wearing shine to keratin fibers, including hair. The compositions comprise an aminosilicone polymer having a viscosity from about 800 to about 1,600 mm2/s at 25° C., and a functional group equivalent weight from about 8,000 to about 14,000 g/mol. The compositions comprise... Agent: Avon Products, Inc.
20140050686 - Agent for keratinous fibers, comprising at least one acrylate/glyceryl acrylate copolymer, at least one film-forming and/or solidifying polymer and at least one ester oil: The present invention is an agent for treating keratinous fibers, particularly human hair, comprising: (a) at least one glyceryl acrylates/acrylates copolymer; (b) at least one film-forming and/or setting polymer; and (c) at least one ester oil. The agent may additionally comprise a polyol such as glycerin. The agent is best... Agent: Henkel Ag & Co. Kgaa
20140050687 - Betaine esters and process for making and using: A variety of betaine esters, including dialkylaminoalkyl cocoate betaines and dialkylaminoalkyl hydrogenated cocoate betaines are disclosed. These betaines can be advantageously prepared in high yield and purity by a three-step transiterification chemoenzymatic process or a two-step direct esterficiation chemoenzymatic process. These betaine esters have excellent surfactant properties.... Agent: Estman Chemical Company
20140050690 - Nanoparticle containing prostaglandin i 2 derivative: There is provided a beraprost sodium-containing nanoparticle that contains beraprost sodium among other prostaglandin I2 (prostacyclin) derivatives, which are therapeutic agents for pulmonary hypertension. The beraprost sodium-containing nanoparticle is obtained by making beraprost sodium hydrophobic using a metal ion and allowing the hydrophobic beraprost sodium to react with poly-L-lactic... Agent: Ltt Bio-pharma Co., Ltd.
20140050689 - Tissue grafted with a biodegradable polymer: Novel implantable tissue fixation methods and compositions are disclosed. Methods and compositions of tissue, fixed using polymeric and/or variable length crosslinks, and di- or polymercapto compounds are described. Also described are the methods and compositions wherein the tissue is fixed using biodegradable crosslinkers. Methods and compositions for making radio-opaque tissue... Agent: Pathak Holdings LLC
20140050691 - Synthesis models for antimicrobial agents via the halogenation of organic/inorganic composites: A method of forming a biocidal halogenated organic/inorganic composite material may include providing at least one inorganic precursor, providing at least one organic agent, precipitating an organic/inorganic composite material by contacting the at least one inorganic precursor with the at least one organic agent, and halogenating the organic/inorganic composite material... Agent:
20140050692 - Polyesters and methods of use thereof: The invention provides polymers and methods for the treatment of pain and inflammation.... Agent: Rutgers, The State University Of New Jersey
20140050693 - Biological active proteins having increased in vivo and/or in vitro stability: Increased in vivo and/or in vitro stability is imparted to a biologically active protein by fusing to an amino acid sequence consisting of at least about 100 amino acid residues, which consist essentially of Alanine, Serine and Proline, which form a random coil conformation. Specific examples are described. Also described... Agent: Technische Universitat Munchen
20140050695 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent:
20140050694 - Method of treating transplant rejection and autoimmune diseases: A method of treating autoimmune diseases and transplant rejection, comprising the step of treating the autoimmune or transplant patient with an effective amount of SU-5416 is disclosed.... Agent: Wisconsin Alumni Research Foundation
20140050696 - Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use: The present invention relates to novel bisaminoquinoline compounds, pharmaceutical compositions comprising these novel compounds and methods for inhibiting autophagy in biological systems. Methods of treating cancer in patients in need using compounds and/or compositions according to the present invention alone or in combination with at least one additional anticancer agent... Agent:
20140050697 - Analysis of hcv genotypes: A method for predicting response of a patient infected with HCV-1a to interferon treatment.... Agent: Vertex Pharmaceuticals Incorporated
20140050699 - Heterocyclic inhibitors of glutaminase: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.... Agent: Calithera Biosciences Inc.
20140050698 - Recombinant super-compound interferon and uses thereof: This invention provides a method for treating tumors in a subject, comprising administering to the subject an effective amount of a recombinant interferon, wherein the interferon has the amino acid sequence of SEQ ID NO:2 and is encoded by the nucleotide sequence SEQ ID NO:1, wherein the tumors are selected... Agent: Superlab Far East Limited
20140050700 - Ex-vivo treatment of peripheral blood leukocytes with ifn-lambda: The present invention provides a method of treating Th2-associated diseases and disorders by modulating the expression or secretion of IL-4, IL-5 and IL-13 using interferon lambda (IFN-λ). For Th2-associated diseases and disorders, cells of a patient having a Th2-associated disease or disorder are treated ex vivo, with IFN-λ and returned... Agent: Medical Diagnostic Laboratories, LLC
20140050701 - Capsid-modified raav vector compositions having improved transduction efficiencies, and methods of use: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration... Agent:
20140050708 - Compositions and methods for treating cancer: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.... Agent: The Trustees Of The University Of Pennsylvania A University
20140050707 - Mir-150 for the treatment of blood disorders: The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively.... Agent: Massachusetts Institute Of Technology
20140050709 - Reversing the effects of the tumor microenvironment using chimeric cytokine receptors: Disclosed are compositions and methods related to rendering ineffective Th1 T cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. Tumor-specific T cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a Th1 immunostimulatory/activating signal. The T cells... Agent: Baylor College Of Medicine
20140050702 - Compositions and methods for reducing blood alcohol content: Disclosed are compositions and methods for reducing blood alcohol content following alcohol consumption. The inventive compositions and methods rapidly reduce blood alcohol content and alleviate symptoms of intoxication in a subject having an elevated blood alcohol content due to alcohol consumption.... Agent: Life Well Lived, LLC
20140050703 - Equol-producing lactic acid bacteria-containing composition: An equol-producing lactic acid bacteria-containing composition comprises, as an essential component thereof, a lactic acid bacterial strain belonging to the genus Lactococcus having an ability to utilize at least one daidzein compound selected from the group consisting of daidzein glycosides, daidzein, and dihydrodaidzein to produce equol. Such a composition is... Agent: Otsuka Pharmaceutical Co., Ltd.
20140050705 - Agent for treating urinary incontinence including stem cells derived from amniotic fluid: The present invention relates to a cell therapy product which is intended for regenerating a sphincter muscle and which contains stem cells derived from amniotic fluid, and more particularly, to a cell therapy product which is intended for regenerating the sphincter vesicae and which contains stem cells derived from amniotic... Agent: Kyungpook National University Hospital
20140050706 - Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation: The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently... Agent:
20140050704 - Stem cell culture method: Methods for culturing pluripotent stem cells on fiber scaffolds are provided which result in the expansion of the number of stem cells without loss of pluripotency. Cells obtained by such methods, implants containing such cells and medical methods using such cells are also disclosed.... Agent: Keele University
20140050710 - Methods for preparing accessory cells and uses thereof for preparing activated nk cells: The present invention relates to a method for preparing accessory cells, said accessory cells may themselves be used for preparing activated NK cells that may be used in various therapeutic protocols (e.g. cancer treatment). More particularly, the present invention relates to a method for preparing an accessory cell comprising the... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)
20140050711 - Production of red blood cells and platelets from stem cells: This disclosure provides methods of making a megakaryocyte-erythroid progenitor cell (MEP), comprising differentiating a stem cell into a MEP in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist. In some embodiments the stem cell is a pluripotent stem cell. In some embodiments the MEP co-expresses CD41 and... Agent:
20140050712 - Disorders implicating pufa oxidation: Some aspects of the invention provide for a method of treating hepatic disorders, lipidemias and cardiac-related risk factors using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.... Agent: Retrotope, Inc.
20140050713 - Chimeric antibacterial polypeptides: Provided herein are antibacterial compositions and methods of making and using the compositions.... Agent:
20140050715 - Protein hydrolysates as agents for overcoming addiction: This invention is directed to the use of a protein hydrolysate, and in particular an egg lysozyme hydrolysate to assist an animal, including a human in overcoming an addition, or by breaking an unwanted habit.... Agent: DsmIPAssets B.v.
20140050714 - Use of hsp70 as a regulator of enzymatic activity: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said... Agent: Orphazyme Aps
20140050717 - Methods for treating bleeding disorders: A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor X1-dependent blood coagulation enhancement in a subject in need of enhanced... Agent:
20140050716 - Novel procoagulant molecular decoy for treating hemophilia a or b with or without inhibitor: The present invention relates to a pharmaceutical composition including a modified factor Xa (GDXa), said modified GDXa being nonthrombogenic, able to bind to TFPI but not able to bind to phospholipids, for preventing or treating a hemorrhagic accident in a patient with hemophilia A or B with or without inhibitor.... Agent: Universite Joseph Fourier (grenoble 1)
20140050718 - Methods and compositions for enhancing intranasal delivery of therapeutic agents: A method for treating a patient suffering from a condition with an active compound comprising the steps of (a) treating the patient intranasally with an effective amount of MMP-9 or a functionally equivalent fragment, wherein the tight junctions of the patient's nasal epithelial cells are modulated or wherein the basal... Agent: Wisconsin Alumni Research Foundation
20140050719 - Antibodies: Antibodies that bind human β-amyloid peptide, methods of treating diseases or disorders characterised by elevated β-amyloid levels or β-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.... Agent: Glaxo Group Limited
20140050721 - Antineoplastic combinations with mtor inhibitor, trastuzumab and/or hki-272: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with... Agent: Wyeth LLC
20140050723 - Cell-penetrating anti-dna antibodies and uses thereof inhibit dna repair: Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA... Agent: Yale University
20140050722 - Chimeric anti-ricin antibody: A chimeric monoclonal antibody targeted to ricin is presented. The light chain and heavy chain constant regions are respectively made up of the light chain and heavy chain constant regions of human immunoglobulin, and the light chain and heavy chain variable regions respectively include the light chain and heavy chain... Agent: Etat Francais Represente Par Le Delegue General Pour L'armement
20140050724 - Compositions and methods: Compositions comprising polyethylene glycol (PEG) are disclosed for the prophylaxis and/or treatment of head and neck squamous cell carcinomas (HNSCC). Methods for the prophylaxis and/or treatment of HNSCC comprising administering an effective amount of PEG are also disclosed. Also disclosed are methods and compositions for suppressing the surface expression of... Agent: Northshore University Healthsystem
20140050720 - Ultralong complementarity determining regions and uses thereof: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob... Agent: The Scripps Research Institute
20140050727 - Anti-cd14 antibody fusion protein: A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.... Agent: Mochida Pharmaceutical Co., Ltd.
20140050725 - Low density lipoprotein - related protein 6 (lrp6) - half life extender constructs: The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased... Agent: Novartis Ag
20140050728 - Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications: Methods and compositions for modulating cyclophilin D, e.g., at least one cyclophilin D biological activity, are provided. Modulation of cyclophilin D is useful in preventing or treating obesity, an overweight condition, or in accommodating a desire to lose weight as well as being useful in treating a variety of kidney... Agent: Board Of Regents Of The University Of Nebraska
20140050726 - Methods and compositions for modulating t cell and/or b cell activation: The present invention provides methods of reducing or enhancing T cell activation and/or B cell activation in a subject, comprising administering to a subject an effective amount of an inhibitor or enhancer, respectively, of Semaphorin 6D (Sema6D) activity on T cells and/or B cells.... Agent: University Of North Carolina At Chapel Hill
20140050729 - Methods for treatment of polyposis: The present invention relates to method for treating medical disorders mediated by mutations in the APC gene by administering an IGF1R inhibitor. Such disorders include, for example, familial adenomatous polyposis (FAP).... Agent:
20140050730 - Methods for diagnosing and treating neuroendocrine cancer: The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed.... Agent: Trustees Of Dartmouth College
20140050731 - Vaccine: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner... Agent: Isis Innovation Ltd.
20140050734 - Antibodies against the s100p protein for the treatment and diagnosis of cancer: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to... Agent:
20140050733 - Apoe immunotherapy: The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.... Agent:
20140050736 - Chemokine receptor binding polypeptides: The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the... Agent: Novartis Ag
20140050732 - Combination for use in the treatment and/or prevention of mastitis: The present invention relates a combination for use in the treatment and/or prevention of mastitis containing i) an agonistic anti-CD40 monoclonal antibody or a CD40 ligand or a vector coding for the anti-CD40 antibody or a vector coding for the CD40L; and ii) inactivated or attenuated bacteria selected from the... Agent:
20140050735 - Treatment of fistulizing chrohn's disease: This invention is in the field of Crohn's disease. In particular, it relates to the treatment of fistulas in Crohn's disease using anti-IL-13 antibodies. The antibody may be an IgG and in particular may be the anti-IL-13 antibody 01951/G12.... Agent:
20140050737 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of... Agent: Onyx Therapeutics, Inc.
20140050738 - Anti-tace antibody molecules and their uses: Anti-TACE (ADAM17) antibodies are disclosed that for the first time in the art are capable of binding to TACE, of acting as antagonists of one or more its biological activities, in particular by binding to TACE in a cross domain binding mode in which residues in both the catalytic domain... Agent: Cancer Research Technology Limited
20140050740 - Compositions and methods for the treatment of tissue fibrosis: Provided are methods of treating tissue fibrosis comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a hyaluron synthase (HAS) or CD44. Further provided are methods of inhibiting myofibroblast invasion, or of reducing matrix deposition in the lung, the methods comprising administering... Agent: Duke University
20140050739 - Local complement inhibition for treatment of complement-mediated disorders: The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof.... Agent: Apellis Pharmaceuticals, Inc.
20140050741 - Synthetic lta mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections: The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.... Agent: UniversitÄ Tsklinikum Freiburg
20140050742 - Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject: Methods of modulating the occurrence of lymphangiogenesis in a subject are provided. In some instances, the method is a method of treating transplant rejection in the subject. Aspects of the methods include administering to the subject an effective amount of: a first antagonist for a tyrosine kinase receptor and a... Agent:
20140050743 - Binding proteins to inhibitors of coagulation factors: The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect... Agent: Bayer Intellectual Property Gmbh
20140050744 - Compositions and methods for the diagnosis and treatment of tumor: The invention is directed to antibody drug conjugate compositions of matter useful for the diagnosis and treatment of tumors in mammals and to methods of using those compositions of matter for the same.... Agent:
20140050746 - Auristatin drug linker conjugates: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.... Agent: Seattle Genetics, Inc.
20140050745 - Melanocortin receptor binding conjugates: The present invention relates to melanocortin receptor binding conjugates and methods of making and using the foregoing.... Agent:
20140050748 - Mutant cd83 promoter and use thereof: The present invention provides a mutant CD83 promoter comprising the promoter/enhancer regions of human CD83 promoter and being dendritic cell-specific, and the use thereof, specifically for the treatment or prevention of diseases or medical conditions related to malignancy, autoimmunity or prevention of transplant rejections.... Agent: Friedrich-alexander-univeristat Erlangen-nurnberg
20140050747 - Trace elements: The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation... Agent: Warburton Technology Limited
20140050751 - Mesothelin vaccines and model systems: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and... Agent: The Johns Hopkins University
20140050749 - Mhc-i restricted epitopes containing non-natural amino acid residues: The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein... Agent: Purdue Pharma L.p.
20140050750 - Vaccine peptide combinations against cat allergy: The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides... Agent: Circassia Limited
20140050754 - Immunogenic chikungunya virus peptides: The present invention relates to immunogenic peptides of Chikungunya Virus and methods for vaccinating a subject using these peptides. Also disclosed are nucleic acids encoding these peptides and methods for their production.... Agent: Agency For Science, Technology And Research
20140050755 - Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions... Agent: Boehringer Ingelheim Vetmedica, Inc.
20140050753 - Polyionic papilloma virus-like particle (vlp) vaccines: The present invention relates to the field of vaccines. In particular, the present invention provides compositions and methods relating to virus-like particle (VLP) vaccines. In one embodiment, a chimeric papillomavirus virus-like particle (VLP) comprises the L1 protein, wherein the HI loop of the L1 protein comprises negatively charged amino acids.... Agent: The Johns Hopkins University
20140050752 - Vaccinia virus polypeptides: This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., membrane proteins such as vaccinia virus B5R, L1R, A33R, or A27L polypeptides). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection... Agent: Mayo Foundation For Medical Education And Research
20140050757 - Compositions and methods for detection of antibodies specific for anaplasma phagocytophilum (aph) and anaplasma platys (apl): The invention provides methods and compositions for the detection and treatment of Anaplasma phagocytophilum and Anaplasma platys infection.... Agent: Idexx Laboratories, Inc.
20140050758 - Fermentation process: e
20140050756 - Novel oprf/i fusion proteins, their preparation and use: The present invention relates to a novel trimeric OprF/I fusion protein comprising a portion of the Pseudomonas aeruginosa outer membrane protein F which is fused with its carboxy terminal end to a portion of the amino terminal end of the Pseudomonas aeruginosa out membrane protein I, wherein said portion of... Agent: Valneva Austria Gmbh
20140050759 - Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the... Agent: Baxter International Inc.
20140050760 - Replication-defective arenavirus vectors: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open... Agent: Universitat Zurich
20140050761 - Crimean-congo hemorrhagic fever virus vaccine: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human... Agent:
20140050762 - Dendritic cells obtained from induced pluripotent stem cells (ipscs): The invention relates to dendritic cells produced from human induced pluripotent stems cells (iPSC). The invention also relates to methods for making and methods of using the dendritic cells of the invention.... Agent: Isis Innovation Limited
20140050763 - Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases: The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating... Agent: Eli Lilly & Company
20140050764 - Inactivated bacterial cell formulation: The invention relates to the use of lactic acid-producing bacteria to boost the immune system.... Agent: Ganeden Biotech, Inc.
20140050765 - Devices and methods for tissue engineering: A resorbable tissue scaffold in a glass ceramic composition forms a rigid three-dimensional porous matrix having a bioactive composition. Porosity in the form of interconnected pore space is provided by the space between the glass-ceramic fiber forming the porous matrix. Strength of the porous matrix is provided by the interconnected... Agent: Bio2 Technologies, Inc.
20140050766 - Tissue engineering construct comprising fibrin: A three-dimensional fibrin engineered tissue construct is provided selected from: (i) a fibrin gel matrix comprising a combination of tissue-specific cells and at least one type of vascular cells; and (ii) a hybrid scaffold of fibrin gel and a polymeric synthetic scaffold comprising at least one type of vascular cells... Agent: Technion Research And Development Foundation Ltd.
20140050768 - Copper-containing metal pigments with a metal oxide layer and a plastic layer, method for the production thereof, coating agent and coated object: The invention relates to copper-containing metal pigments, wherein the copper-containing metal pigments have an elemental copper content of at least 50 wt. %, relative to the total weight of the uncoated copper-containing metal pigment, wherein the copper-containing metal pigments have at least one enveloping metal oxide layer and at least... Agent: Eckart Gmbh
20140050767 - Epidermal cooling: In one aspect, an epidermal coolant includes a porous material and a phase change material retained in the porous material. The phase change material has a melting point between about 0-degrees Celsius and about 65-degrees Celsius and is retained in the porous material when the phase change material is in... Agent: Exert Co.
20140050770 - Powdery cosmetic composition: The present invention relates to a cosmetic composition comprising a pulverulent phase comprising at least one composite powder including titanium dioxide and magnesium oxide. The cosmetic composition according to the present invention is at least comparable in terms of cosmetic effects with conventional cosmetic compositions comprising a conventional composite powder... Agent: L'oreal
20140050769 - Silver coating pigment, and method for producing same: Disclosed is a method for producing a silver (Ag) coating pigment. The method for producing a silver coating pigment according to the present invention comprises: a step of forming a tin compound pretreatment layer on the matrix surface; and a step of forming a silver coating layer on the lower... Agent: Cqv Co., Ltd.
20140050771 - Pdgf induced cell homing: Provided is a method of causing a cell to migrate to a scaffold. Also provided is a method of treating a mammal that has a tissue defect. Further provided is a tissue scaffold comprising platelet-derived growth factor (PDGF). Additionally, a method of making a tissue scaffold capable of recruiting a... Agent: The Trustees Of Columbia University In The City Of New York
20140050772 - Methods for treating conditions of the nail unit: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include non-temperature dependent phase change compositions that may be formulated as solutions, solids, semisolids, microparticles, or crystals.... Agent: Hallux. Inc.
20140050773 - Compound comprising alpha-msh for use in endodontic regeneration: The present invention concerns a compound comprising an α-MSH peptide, coupled to a polypeptide consisting of a chain of about 15 to about 400 amino acids, for use in endodontic regeneration and/or for the treatment of dental inflammatory diseases. The invention further concerns pharmaceutical compositions, in particular nanostructured compositions, comprising... Agent: Universite De Strasbourg
20140050774 - Wound treatment therapy: The wound treatment therapy deactivates pathogenic microorganisms within the wound environment without disrupting the cell walls. The wound treatment therapy of this invention combines the application of stabilized hypochlorous acid compound with the application of a hydrophobic wound dressing. The application of hypochlorous acid provides the initial anti-microbial agent, which... Agent: Integrated Healing Technologies, LLC
20140050780 - Liposomal formulation of nonglycosidic ceramides and uses thereof: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases... Agent: Ludwig Institute For Cancer Research Ltd.
20140050777 - Liposomal formulations of polymyxin and uses thereof: The present invention provides novel liposomal formulations of polymyxin B and pharmaceutical compositions thereof useful for the treatment of bacterial infections. The liposomal formulation comprises a lipid component formed as vesicles each having a minimum size of at least 500 nm and polymyxin B encapsulated in the vesicles. The present... Agent:
20140050776 - Novel method for preventing or treating m tuberculosis infection: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic... Agent: Glaxosmithkline Biologicals Sa
20140050778 - Nucleic acid binding compounds, methods of making, and use thereof: The present invention relates to oligomer compounds, including dimers and trimers, formed by a disulfide, sulfinyl thio, olefin or hydrocarbon bond, or a hydrazone exchange bond between two or more monomers. Methods of making the monomers and the oligomers is also disclosed. Use of the compounds for inhibiting the activity... Agent: University Of Rochester
20140050775 - Polyamine derivatives: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.... Agent: Egen, Inc.
20140050779 - Transglutaminase-2 inhibitors and uses thereof: The present invention refers to a method of treating a disease or disorder associated with the expression of at least one transgluaminase-2 and a method of identifying a candidate transglutaminase-2 inhibitor.... Agent: Singapore Health Services Pte. Ltd.
20140050781 - Use of agr3 for treating cancer: Embodiments are related to processes for using an Anterior Gradient Homolog 3 (AGR3) therapeutic to treat an enhanced AGR2 expressing cancer, or its premalignant precursor, comprising administering an amount of an AGR3 therapeutic to a human patient in need thereof.... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20140050782 - Layered bodies, compositions containing them and processes for producing them: A layered body comprising: a core region; at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer, wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one... Agent: Ucl Business PLC
20140050783 - Methods and compositions for sleep disorders and other disorders: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or... Agent: Intra-cellular Therapies Inc.
20140050784 - Pharmaceutical compositions of memantine: The present invention relates to oral dosage forms comprising Memantine or a pharmaceutically acceptable salt thereof, pharmaceutical formulations comprising the oral dosage forms, and methods for treating mild, moderate or severe Alzheimer's dementia, or neuropathic pain comprising the oral dosage forms and formulations.... Agent: Teva Pharmaceutical Industries Ltd.
20140050785 - Dissolution properties of drug products containing olmesartan medoxomil: A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. The composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method for treating or preventing hypertension by administering the pharmaceutical tablet to a patient.... Agent: Daiichi Sankyo Company, Limited
20140050786 - Combination of triazine derivatives and insulin sensitisers: The present invention relates to combinations of triazine derivatives and of insulin sensitisers.... Agent: Poxel Sas
20140050787 - Pharmaceutical compositions resistant to abuse: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.... Agent: Egalet Ltd.
20140050788 - Micronized placental tissue compositions and methods of making and using the same: Described herein are compositions composed of micronized placental components, extracts of micronized placental components, and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions and the extracts thereof are also described herein.... Agent: Mimedx Group Inc.
20140050789 - Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids: Provided are compositions comprising a benzodiazepine and a neurosteroid, containing one or both of the benzodiazepine and the neurosteroid in a subtherapeutic dose, and administration of such compositions for mitigation of an epileptic seizure. Further provided are compositions comprising a benzodiazepine, a neurosteroid, and an NMDA blocker, and administration of... Agent: The Regents Of The University Of California
20140050791 - Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size: The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The inventions further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of... Agent: Dr. Falk Pharma Gmbh
20140050792 - Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the... Agent: Dow Pharmaceutical Sciences, Inc.
20140050790 - Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel: The invention relates to an oleogel-forming agent which comprises at least one highly dispersed triterpene. The invention also relates to an oleogel which comprises a nonpolar liquid in an amount ranging from 80% by weight to 99% by weight based on the total weight of the oleogel and an oleogel-forming... Agent: Birken Gmbh
20140050795 - Binder powders: The present disclosure relates generally to binder powders for use in powder material processing and processes for their preparation. The disclosure further relates to binder powders for use in making solid powder compact forms, solid powder compact forms containing said binder powders and methods for making solid powder compact forms.... Agent: Monash University
20140050793 - Novel compositions for inhibiting virus entry and promoting virolysis, and methods thereof: The present invention includes a composition comprising a gold nanoparticle complexed with a cysteine-containing peptide. The invention also includes the method of preparing a composition comprising a gold nanoparticle complexed with a cysteine-containing peptide. The invention further includes a method of causing virolysis of a virus using the compositions described... Agent: Drexel University
20140050794 - Pharmaceutical composition for use as a contraceptive: In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and... Agent:
20140050796 - Composition comprising a mixture of dextro- and levo- amphetamines complexed with ion-exchange resin particles to form drug resin particles: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. In a particular embodiment, the drug dosage form comprises a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles.... Agent: Neos Therapeutics, Lp
20140050797 - Drug delivery systems comprising solid solutions of wealkly basic drugs: The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the... Agent:
20140050798 - Sustained-release nanoparticle compositions and methods using the same: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.... Agent: Board Of Regents Of The Univ. Of Nebraska By And Behalf Of The University Of Nebraska Medical Cente
20140050799 - Risperidone sustained release microsphere composition: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity... Agent: Shandong Luye Pharmaceutical Co., Ltd.
20140050800 - Method of reducing oxidative stress: Methods of ameliorating cellular oxidative stress and reducing serum cholesterol are disclosed.... Agent:
20140050801 - Gas dissolving apparatus: A gas dissolving apparatus that combines a gas at first pressure into a working fluid, the working present at a second pressure equal to or greater than the first pressure. The device includes a molecular mixing chamber which is designed as a truncated conical chamber located between an inlet... Agent: G Tech Licensing, LLC
20140050802 - Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects: The present invention relates to compositions and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the composition provides a nutritional supplement with a beneficial increased supplementation of vitamin D and the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine,... Agent: Everett Laboratories, Inc.
20140050803 - Compositions and methods for treatment of melanoma: Described herein are compositions and methods for the prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated with melanoma or with melanoma brain tropism, as well as various nucleic acid molecules relating thereto or derived therefrom.... Agent: New York University
20140050804 - Cold infusion process for fortifying corn and/or soybeans: This invention relates to a cold infusion process for fortifying corn and/or soybeans with one or more vitamin, non-vitamin, mineral, non-mineral, botanical, hormone, herb, neutraceutical, lipid, carbohydrate, amino acid, acid, salt, prebiotic, or probiotic functional additives. This invention also discloses an infused corn and/or soybean produced by the process of... Agent: Voyava Republic LLC
20140050805 - Composition, glucose metabolism-improving agent, and method for improving glucose metabolism: A composition, including: (A) Panax notoginseng; and at least one of (B) a Piper longum extract and (C) vitamin B1, a salt thereof or a derivative thereof.... Agent: Lion Corporation
20140050806 - Method, apparatus and kit for the treatment of neurodegenerative diseases and impairments: A method, apparatus and kit have been discovered which regenerate with the use of odorants the connections of the neurons of the brain and central nervous system in the treatment of such person afflicted neuro-disorders caused by disease or trauma.... Agent:
20140050807 - Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof: The invention provides compositions containing omega-3 oil and at least one anti-inflammatory agent and/or at least one gastrotoxic, nephrotoxic, or hepatotoxic pharmaceutical agent. The invention further provides kits containing these compositions and methods for decreasing pain or inflammation, decreasing the symptoms of an allergic condition, and/or the gastrotoxicity, nephrotoxicity, and... Agent:
20140050808 - Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care: A stabilized formulation for skin care, wound care and/or other tissue healing applications and methods for making the same is described. The stabilized formulation stabilizes omega-3 polyunsaturated fatty acids and is constituted of the omega-3 polyunsaturated fatty acids in combination with tocopherol (Vitamin E), ascorbic acid (Vitamin C), herb extract,... Agent: Kerecis Ehf
20140050809 - Non-toxic pest repellent for use on humans/animals: This invention relates generally to a non-toxic insect repellent comprising natural ingredients for application on humans and or animals. More particularly, the present invention is directed toward a non-aerosol insect repellent for application to the skin or clothing of humans and animals to repel pests found in a variety of... Agent:
20140050810 - Anti-obesity composition comprising lycium chinensis leaf extract and betaine as active ingredient: Disclosed are betaine and a Lycium chinensis leaf extract and a mixture thereof which are preventive and therapeutic of obesity, and uses thereof. They are found to have prophylactic and therapeutic effects on obesity and obesity-induced metabolic syndrome as evaluated for reductive activity against weight, body fat, total cholesterol, triglyceride,... Agent: Bionutrigen Co., Ltd.Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20140227:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
FreshPatents.com Support - Terms & Conditions
Results in 1.50489 seconds